FarmaMondo has been appointed to exclusively manage the access of Carmustine Obvius to Italian healthcare providers looking to fulfill unmet medical needs of patients with brain tumors and Hodgkin’s /non-Hodgkin’s lymphomas, types of cancer that originate from white blood. As the product will not be commercially launched in Italy FarmaMondo will provide a managed access service on a direct to HCP distribution model.
Carmustine is indicated as palliative therapy as a single agent or in established combination therapy with other approved chemotherapeutic agents in Brain tumors – (glioblastoma, medulloblastoma, astrocytoma and metastatic brain tumors), Multiple myeloma, Hodgkin’s disease and Non-Hodgkin’s lymphomas.
Carmustine Obvius was approved by EMA on June, 2018. It is currently the only EMA centrally approved product with such indication.
FarmaMondo is a Swiss-based pharmaceutical company with a focus on providing paid access to unlicensed medicines. Our global footprint includes commercial operations in more than 70 markets, headquartered from Switzerland with regional hubs in Europe, Asia and Latin America.
For more information about FarmaMondo please visit www.farmamondo.com.
For all inquiries regarding Carmustine Obvius®, please contact
Phone: +41 91 6976390
Obvius investment BV is the global rights holder to commercialize the product Carmustine Obvius, licensed from the developer MERR Holding.